(Q46604911)

English

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion

scientific article published in November 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Seung Kew Yoon

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Jeong Won Jang

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Chang Wook Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Si Hyun Bae

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Jong Young Choi

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Sang Wook Choi

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Young Sok Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Chang Don Lee

8

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Kyu Won Chung

9

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Hee Sik Sun

10

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Boo Sung Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

publication date

1 November 2005

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

48

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

6

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

341-349

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Viral features of lamivudine resistant hepatitis B genotypes A and D.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1159%2F000086061

21 January 2018

Identifiers

10.1159/000086061

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/16024938

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46604911&oldid=2121706929"